Skip to main content

Table 2 Baseline characteristics of breast cancer patients with liver metastases in the FUSCC dataset

From: Risk and prognostic factors of breast cancer with liver metastases

Variable Patients, No. %
Patients (n = 1728)
Age at diagnosis, y
 21–40 288 (16.7%)
 41–60 1143 (66.1%)
  > 60 297 (17.2%)
Histology
 Infiltrating duct carcinoma 1396 (80.8%)
 Lobular carcinoma 31 (1.8%)
 Other 301 (17.4%)
De novo metastatic diseases
 No 1526 (88.3%)
 Yes 202 (11.7%)
Surgery of primary site
 No 219 (12.7%)
 Yes 1509 (87.3%)
Prior Chemotherapy
 No 226 (13.1%)
 Yes 1502 (86.9%)
Prior Radiotherapy
 No 848 (49.1%)
 Yes 785 (45.4%)
 Unknown 95 (5.5%)
Recurrent sequence
 First liver metastases 1087 (62.9%)
 Subsequent liver metastases 641 (37.1%)
Extrahepatic metastatic sites to lung, brain, bone and lymph nodes, No
 0 561 (32.5%)
 1 534 (30.9%)
 2 382 (22.1%)
 3 223 (12.9%)
 All 4 28 (1.6%)
Subtype
 HR+/HER2− 767 (44.3%)
 HR+/HER2+ 305 (17.7%)
 HR−/HER2+ 321 (18.6%)
 Triple-negative 270 (15.6%)
 Unknown 65 (3.8%)
  1. Notes: + denotes positive; − denotes negative; *denotes a statistically significant P-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor